Gain Therapeutics Analyst Price Targets

Wall Street analyst price targets and consensus rating for Gain Therapeutics (GANX).

Price Target Range — 12 Quarters

Analyst Consensus — 7 Analysts

7Buy

Consensus RatingBuy# Analysts7Avg. Consensus PT$8Upside to Avg. PT+472.7%

Rating Trend — Last 9 Months

Recent Analyst Actions

모든 평가 보기 →

Date	Firm	Analyst	Action	Rating Change	Price Target
Oct 5, 2026	HC Wainwright & Co.	Raghuram Selvaraju	Maintained	Buy	$8
Aug 31, 2026	HC Wainwright & Co.	Raghuram Selvaraju	Maintained	Buy	$8
Aug 11, 2026	BTIG	Thomas Shrader	Maintained	Buy	$5
Jul 1, 2026	HC Wainwright & Co.	Raghuram Selvaraju	Maintained	Buy	$8
Jun 30, 2026	BTIG	Thomas Shrader	Maintained	Buy	$5
Dec 19, 2025	HC Wainwright & Co.	Raghuram Selvaraju	Maintained	Buy	$8
Oct 16, 2025	BTIG	Thomas Shrader	PT Cut	Buy	$9→$5
Oct 15, 2025	BTIG	Thomas Shrader	Maintained	Buy	$9
Oct 13, 2025	HC Wainwright & Co.	Raghuram Selvaraju	Maintained	Buy	$8
Oct 7, 2025	Maxim Group	Jason McCarthy	PT Raise	Buy	$5→$7
Sep 8, 2025	BTIG	Thomas Shrader	Maintained	Buy	$9
Aug 13, 2025	Roth Capital	Boobalan Pachaiyappan	PT Cut	Buy	$7→$6
Jul 3, 2025	HC Wainwright & Co.	Raghuram Selvaraju	Maintained	Buy	$8
May 19, 2025	HC Wainwright & Co.	Raghuram Selvaraju	Maintained	Buy	$8
Mar 28, 2025	Chardan Capital	Keay Nakae	Maintained	Buy	$6
Mar 17, 2025	HC Wainwright & Co.	Raghuram Selvaraju	Maintained	Buy	$8
Mar 7, 2025	Scotiabank	Louise Chen	Initiate	Sector Outperform	$12
Dec 24, 2024	Roth MKM	Boobalan Pachaiyappan	Maintained	Buy	$7
Dec 5, 2024	Roth MKM	Boobalan Pachaiyappan	Initiate	Buy	$7
Nov 25, 2024	HC Wainwright & Co.	Raghuram Selvaraju	Maintained	Buy	$8

More with Benzinga EdgeGet Access

Analyst Ratings News

PRO
HC Wainwright & Co. Reiterates Buy on Gain Therapeutics, Maintains $8 Price Target

HC Wainwright & Co. analyst Raghuram Selvaraju reiterates Gain Therapeutics (NASDAQ:GANX) with a Buy and maintains $8 price target.

Benzinga Newsdesk

PRO
HC Wainwright & Co. Reiterates Buy on Gain Therapeutics, Maintains $8 Price Target

HC Wainwright & Co. analyst Raghuram Selvaraju reiterates Gain Therapeutics (NASDAQ:GANX) with a Buy and maintains $8 price target.

Benzinga Newsdesk

PRO
HC Wainwright & Co. Reiterates Buy on Gain Therapeutics, Maintains $8 Price Target

HC Wainwright & Co. analyst Raghuram Selvaraju reiterates Gain Therapeutics (NASDAQ:GANX) with a Buy and maintains $8 price target.

Benzinga Newsdesk

PRO
HC Wainwright & Co. Reiterates Buy on Gain Therapeutics, Maintains $8 Price Target

HC Wainwright & Co. analyst Raghuram Selvaraju reiterates Gain Therapeutics (NASDAQ:GANX) with a Buy and maintains $8 price target.

Benzinga Newsdesk

PRO
BTIG Reiterates Buy on Gain Therapeutics, Maintains $9 Price Target

BTIG analyst Thomas Shrader reiterates Gain Therapeutics (NASDAQ:GANX) with a Buy and maintains $9 price target.

Benzinga Newsdesk

PRO
HC Wainwright & Co. Reiterates Buy on Gain Therapeutics, Maintains $8 Price Target

HC Wainwright & Co. analyst Raghuram Selvaraju reiterates Gain Therapeutics (NASDAQ:GANX) with a Buy and maintains $8 price target.

Benzinga Newsdesk

Gain Therapeutics Inc

뉴스

파트너 / 기고자

벤징가 글로벌

Gain Therapeutics Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PRO
HC Wainwright & Co. Reiterates Buy on Gain Therapeutics, Maintains $8 Price Target

PRO
HC Wainwright & Co. Reiterates Buy on Gain Therapeutics, Maintains $8 Price Target

PRO
HC Wainwright & Co. Reiterates Buy on Gain Therapeutics, Maintains $8 Price Target

PRO
HC Wainwright & Co. Reiterates Buy on Gain Therapeutics, Maintains $8 Price Target

PRO
BTIG Reiterates Buy on Gain Therapeutics, Maintains $9 Price Target

PRO
HC Wainwright & Co. Reiterates Buy on Gain Therapeutics, Maintains $8 Price Target

People Also Watch

People Also Watch

Gain Therapeutics Inc

뉴스

파트너 / 기고자

벤징가 글로벌

Gain Therapeutics Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PROHC Wainwright & Co. Reiterates Buy on Gain Therapeutics, Maintains $8 Price Target

PROHC Wainwright & Co. Reiterates Buy on Gain Therapeutics, Maintains $8 Price Target

PROHC Wainwright & Co. Reiterates Buy on Gain Therapeutics, Maintains $8 Price Target

PROHC Wainwright & Co. Reiterates Buy on Gain Therapeutics, Maintains $8 Price Target

PROBTIG Reiterates Buy on Gain Therapeutics, Maintains $9 Price Target

PROHC Wainwright & Co. Reiterates Buy on Gain Therapeutics, Maintains $8 Price Target

People Also Watch

People Also Watch

PRO
HC Wainwright & Co. Reiterates Buy on Gain Therapeutics, Maintains $8 Price Target

PRO
HC Wainwright & Co. Reiterates Buy on Gain Therapeutics, Maintains $8 Price Target

PRO
HC Wainwright & Co. Reiterates Buy on Gain Therapeutics, Maintains $8 Price Target

PRO
HC Wainwright & Co. Reiterates Buy on Gain Therapeutics, Maintains $8 Price Target

PRO
BTIG Reiterates Buy on Gain Therapeutics, Maintains $9 Price Target

PRO
HC Wainwright & Co. Reiterates Buy on Gain Therapeutics, Maintains $8 Price Target